Blog
RSS FeedPosted by Michael Wonder on 19 Jan 2025
Aprocitentan approved to treat adults with hypertension whose blood pressure cannot be controlled by other medications
17 January 2025 - The MHRA has approved the medicine aprocitentan (Jeraygo) to treat hypertension in adults whose blood pressure cannot ...
Posted by Michael Wonder on 17 Jan 2025
Seladelpar approved to treat adult patients in the UK with liver illness
16 January 2025 - As with any medicine, the MHRA will keep the safety and effectiveness of seladelpar under close review. ...
Posted by Michael Wonder on 11 Dec 2024
Delgocitinib approved to treat adult patients with moderate to severe chronic hand eczema
10 December 2024 - The MHRA has approved the medicine delgocitinib (Anzupgo) to treat moderate to severe chronic hand eczema in ...
Posted by Michael Wonder on 11 Oct 2024
MHRA approves Comirnaty KP.2 COVID-19 vaccine for adults
10 October 2024 - The MHRA has today approved an adapted Pfizer/BioNTech COVID-19 vaccine (Comirnaty) that targets the KP.2 COVID-19 sub-variant ...
Posted by Michael Wonder on 28 Sep 2024
MHRA approves first medicine for rare immune disease APDS
27 September 2024 - The MHRA has on 25 September approved leniolisib phosphate (Joenja) to treat a rare immune disease known ...
Posted by Michael Wonder on 09 Sep 2024
Celltrion’s Stelara biosimilar secures UK approval
4 September 2024 - Celltrion said its Stelara (ustekinumab) biosimilar, Steqeyma, received marketing authorisation from the UK MHRA. ...
Posted by Michael Wonder on 15 Aug 2024
Zolbetuximab approved to treat adults with stomach or gastro-oesophageal junction cancer
14 August 2024 - A new targeted cancer treatment, given in combination with a standard chemotherapy, for adults with stomach (gastric) ...
Posted by Michael Wonder on 26 Jul 2024
MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults
23 July 2024 - Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those ...
Posted by Michael Wonder on 02 Mar 2024
MHRA grants first approval via the new International Recognition Procedure in 30 days
1 March 2024 - Launched in January 2024, IRP aims to further help bring life-saving new medicines to UK patients without ...
Posted by Michael Wonder on 22 Feb 2024
UK's MHRA revokes authorisation for Novartis' sickle cell drug
21 February 2024 - Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle ...
Posted by Michael Wonder on 29 Jan 2024
Rezzayo approved to treat adult patients with invasive candidiasis
29 January 2024 - The MHRA has today approved the medicine Rezzayo (rezafungin) to treat a fungal infection called invasive candidiasis. ...
Posted by Michael Wonder on 15 Jan 2024
Santhera receives approval for Agamree (vamorolone) as a treatment for Duchenne muscular dystrophy in the United Kingdom
12 January 2024 - Launches of Agamree in Europe, with Germany taking the lead, are planned to start in Q1, ...
Posted by Michael Wonder on 03 Jan 2024
MHRA’s new international recognition procedure goes live from 1 January 2024
2 January 2024 - In partnership with other global regulators, the international recognition procedure is expected to further help bring life-saving ...
Posted by Michael Wonder on 04 Aug 2017
How much should we spend on health care?
3 August 2017 - What’s the right amount of spending on health care? And how does the UK’s spending compare ...
Posted by Michael Wonder on 23 Sep 2015
No evidence that £1bn Cancer Drugs Fund has helped patients, says watchdog
17 September 2015 - There is no way of knowing whether the Cancer Drugs Fund, which has cost the NHS £1bn ...